Update on pharmacology of obesity: benefits and risks.

Author: Cabrerizo GarcíaLucio, Moreno LoperaCarmen, Ramos-LevíAna, Rubio HerreraMiguel A

Paper Details 
Original Abstract of the Article :
The prevalence of obesity in Western countries has increased at a much greater pace than the development of new efficient and safe drugs, beyond mere lifestyle changes, for the treatment of overweight. Numerous different types of drugs which had been used in the past for the treatment of obesity hav...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.3305/nh.2013.28.sup5.6927

データ提供:米国国立医学図書館(NLM)

The Elusive Quest for Obesity Treatment: A Pharmacological Perspective

Obesity is a global health challenge, akin to a vast desert of challenges facing individuals and healthcare systems. This study explores the complex landscape of pharmacological treatments for obesity, highlighting the need for more effective and safe drugs beyond lifestyle interventions. The study delves into the history of obesity medications, noting that many previously used drugs were withdrawn due to undesirable side effects, like mirages in the desert that lured travelers astray. The study points to the limited availability of effective obesity medications in Europe, with only orlistat currently approved, while the US has a few additional options, such as diethylpropion and phentermine. However, even these options have limitations and are often used for short-term periods. Recent FDA approvals of lorcaserin and the combination phentermine/topiramate, like newly discovered oases, offer hope but need further investigation. Lorcaserin, a selective serotonin 2C receptor agonist, works by decreasing food intake, while the phentermine/topiramate combination has shown significant weight reduction. The study emphasizes the need for continued research to develop new and effective treatments for obesity, recognizing that the desert of obesity remains a challenging terrain.

A Promising Oasis in the Desert of Obesity

The study highlights the promising developments in obesity treatment with the recent FDA approval of lorcaserin and the combination phentermine/topiramate. These drugs, like newly discovered oases, provide hope for individuals struggling with obesity. The study also underscores the importance of continued research, recognizing that the desert of obesity remains vast and complex. Further exploration is needed to develop new and effective treatments, ensuring that these oases are not merely mirages.

Navigating the Desert of Obesity: A Path Towards Well-being

The study emphasizes the importance of pursuing a multi-pronged approach to managing obesity, combining lifestyle changes with appropriate medical interventions. It's like navigating a desert with a map, compass, and a reliable guide. The study highlights the need for caution and informed decision-making when considering medications for obesity, considering both potential benefits and risks. This knowledge empowers individuals to make informed choices and navigate the challenging terrain of obesity with greater awareness and control.

Dr.Camel's Conclusion

The quest for effective and safe obesity treatments continues, mirroring the ongoing exploration of a vast and challenging desert. This study provides valuable insights into the current landscape of pharmacological interventions, emphasizing the need for continued research and personalized approaches to manage this complex health condition. Only by understanding the desert's intricacies and identifying new oases can we find a sustainable path towards well-being.

Date :
  1. Date Completed 2014-06-25
  2. Date Revised 2013-09-09
Further Info :

Pubmed ID

24010752

DOI: Digital Object Identifier

10.3305/nh.2013.28.sup5.6927

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.